Cefotetan (CAS 69712-56-7)

Cefotetan, a second-generation cephalosporin antibiotic, has been a subject of extensive scientific research due to its potent antimicrobial activity and unique mechanism of action. Recent studies have explaind its mechanism, revealing its ability to inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cefotetan targets specific PBPs, particularly PBP3, which plays a crucial role in the final stages of peptidoglycan synthesis during bacterial cell wall assembly. By binding to PBP3, cefotetan disrupts the cross-linking of peptidoglycan chains, leading to weakened bacterial cell walls and eventual cell lysis. This mechanism confers broad-spectrum activity against a wide range of Gram-positive and Gram-negative bacteria, including many clinically relevant pathogens. Moreover, cefotetan has been investigated for its potential applications in combination therapies and synergistic interactions with other antibiotics. Additionally, researchers have utilized cefotetan as a tool compound in microbiology research, facilitating the study of bacterial cell wall biosynthesis and mechanisms of antibiotic resistance. Its potent antimicrobial activity and unique mechanism make cefotetan a valuable asset in antimicrobial research, offering insights into bacterial cell biology and potential strategies for combating antibiotic-resistant infections.